🧠🆕 phase 3 GEMZ data show consistent seizure reductions with fenfluramine across age groups in CDD
📊 Median countable motor seizure frequency:
⬇️ 45.7% in children aged 2–6 years
⬇️ 48.2% in patients older than 6 years
Findings presented at #CNS2026: www.neurologylive.com/view/fenflur...
#Epilepsy
